Kopra Bio
Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.
Y Combinator
yc-company-directory #2809Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.
sourceKopra Bio is classified as AI infrastructure from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Kopra Bio
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
Ditto Biosciences
match 68Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology. Viruses, ticks, and worms have experimented over millions of years to create proteins that control the human immune system. We use AI to identify these proteins and engineer them into next-generation autoimmune therapies. Our team is three PhD scientists from UCSF, UCSD, and UC Berkeley who have worked together for 3+ years in biotech. We have deep expertise in parasite biology, computational biology, and software
shared product terms: bio, drug, viruse, immune; same category: AI infrastructure; shared affiliation: Y Combinator
Notable Labs
match 57Notable Labs is building a personalized drug discovery platform to identify treatment options for relapsed and refractory cancer patients — starting with blood cancer — to address the long tail of cancer treatment. We look at a person’s actual cancer cells, test combinations of FDA approved drugs, and see which combinations kill the cancer cells and leave the healthy cells alive. We focus on combinations because cancer is often difficult to target with just one drug and starting with a single dr
shared product terms: kill, cancer, drug, start; shared affiliation: Y Combinator
Lygg
match 49Up to 90% of skin aging is caused by UV light from the sun. Most of this is caused by UVA light and only one FDA-approved chemical ingredient protects against it. To address this, Lygg has developed a patented, photostable, and safe ingredient that triples current UVA protection.
shared product terms: develop, most, current, fda; shared affiliation: Y Combinator
Eris Biotech
match 49We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.
shared product terms: develop, cancer, immune, drug; shared affiliation: Y Combinator
Evolvere BioSciences
match 44🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein inter
shared product terms: model, next, current, drug; same category: AI infrastructure; shared affiliation: Y Combinator
Humane Genomics
match 41Humane Genomics has developed a platform to engineer cancer killing viruses. We have taken a first principles approach to design and make oncolytic viral therapies. Using a highly lytic RNA virus engineered with "2 factor authentication" (using selective infection and selective replication) they have an on-target to off-target kill ratio > 1000. We are working on our first indication, pediatric liver cancer (hepatoblastoma), with our partners at Texas Children's Hospital, who are world leading e
shared product terms: develop, engineer, cancer, kill; shared affiliation: Y Combinator